Benefits and Risks of Pharmacological Treatments for Essential Tremor
Kelly E. Lyons(University of Kansas Medical Center), Ray L. Watts(University of Alabama at Birmingham), William C. Koller(Stanford University), Rajesh Pahwa(University of Kansas Medical Center), Stanley Fahn(Columbia University Irving Medical Center), Mahmood Eisa(Pennsylvania Hospital), Caroline M. Tanner(NewYork–Presbyterian Hospital), Kapil D. Sethi(Augusta University), Cynthia Comella(Rush University Medical Center), Joseph Jankovic(Baylor College of Medicine), William G. Ondo(Houston Methodist), Matthew B. Stern(University of Pennsylvania Health System), Ron Tintner(Baylor College of Medicine), Jorge L. Juncos(Emory University), Rodger J. Elble
Cited by 103
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
|Nature Genetics|1997|1k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846